哌拉西林/他唑巴坦耐药大肠埃希菌感染的危险因素分析

Analysis of risk factors for piperacillin/tazobactam resistant Escherichia coli infection among hospitalizd patients

目的探讨住院患者哌拉西林/他唑巴坦(PIP-TAZ)耐药大肠埃希菌感染的危险因素。方法回顾该院2011年1～12月,从不同住院患者标本分离出的825株大肠埃希菌的临床资料,以PIP-TAZ敏感株为对照,分析PIP-TAZ耐药株感染的危险因素。结果 Logistic回归分析表明阿莫西林(AMOX)或阿莫西林/克拉维酸(AMC)的使用(OR=2.058,95%CI:1.237～3.430)和ICU入住比例(OR=1.871,95%CI:1.051～3.329)是PIP-TAZ耐药大肠埃希菌感染的独立危险因素。PIP-TAZ耐药大肠埃希菌感染者的平均住院时间长于敏感株(t=14.1,P<0.05)。结论对AMOX或AMC使用的控制有助于预防PIP-TAZ耐药菌感染在住院患者中的扩散。

Objective To investigate the risk factors for piperacillin/tazobactam（PIP TAZ） resistant Escherichia. coli infection among inpatients. Methods This study was a retrospective review of clinical data of inpatients in our hospital from January to De- cember 2011. 825 strains of Escherichia coli were isolated from those inpatients＇ clinical samples respectively. Using the PIP TAZ sensitivity Escherichia coli strains as the control group,the risk factors for the PIP-TAZ resistant were analyzed. Results Logistic regression analysis showed amoxicillin or amoxicillin/clavulanic acid（OR=2. 058,95%CI：1. 237 3. 430） and ICU occupancy rate （OR= 1.871,95 % CI：1. 051- 3. 329） were independent risk factors for PIP-TAZ resistance Escherichia coli infection. The duration of hospitalization were longer in the case of infections with PIP-TAZ resistant Escherichia coli than sensitive strains（t=14.1 ,P〈0.05）. Conclusion Controlling the use of AMOX or AMC can help prevent the PIP-TAZ resistant Escherichia coli infection spread among inpatients.